Literature DB >> 2101203

Study of specific immune response to unadsorbed concentrated tetanus vaccine administered by intradermal route to non-immunized persons in the last ten years.

G Dimache1, C Stoean, S Durbacă, M Croitoru, M Ionescu, I N Nedelcu, I Corbu.   

Abstract

Investigations of anti-tetanus response, in 404 subjects, most of them aged 60, being non-immunized for at least 10 years, stressed out the fact that 28.7% were not protected and 6.18% presented a protecting titer of 0.01 IU/ml, evaluated by "in vivo" protection test in mice. Some subjects were immunized with unadsorbed Tetanus vaccine (10 Lf/0.1 ml/dose) by i.d. route, using Jet-injector, and the others with adsorbed Tetanus vaccine (0.5 ml/dose), by i.m. route, using the needle and syringe. The vaccines were well tolerated and adverse reactions were not recorded. After 30 days, a single vaccine dose produced a protecting effect in 97.45% of non-protected subjects, belonging to i.d. immunized group, and also in 93.33% belonging to i.m. immunized group. 30 days after the administration of a second dose, protection set up in all subjects, no matter of vaccine type and administration route used. For a continuous reduction of tetanus morbidity, the authors suggest a specific periodical immunization of non-protected persons, selected by serological screening, using unadsorbed Tetanus vaccine, administered by i.d. route by means of the Jet-injector.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2101203

Source DB:  PubMed          Journal:  Arch Roum Pathol Exp Microbiol        ISSN: 0004-0037


  2 in total

Review 1.  Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Authors:  Yotam Levin; Efrat Kochba; Ivan Hung; Richard Kenney
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Delivery systems for intradermal vaccination.

Authors:  Y C Kim; C Jarrahian; D Zehrung; S Mitragotri; M R Prausnitz
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.